Sandoz management is preparing to set out detailed plans for the soon-to-be standalone company at a capital markets day on 8 June, as the firm gets closer to being spun off from parent company Novartis.
With industry onlookers eager to learn more about the generics and biosimilars specialist’s future plans, Generics Bulletin traces the path...